

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- Acquired bleeding disorders, 37-57
 - acquired combined inhibitor to factor V and thrombin, 55
 - acquired inhibitors to factor V, 53-55
 - acquired inhibitors to factor VIII, 51-53
 - disseminated intravascular coagulation (DIC), 37-44
 - idiopathic thrombocytopenic purpura (ITP), 55-56
 - liver disease, 44-48
 - vitamin K deficiency, 48-51
- Acquired combined inhibitor to factor V and thrombin, 55
- Acquired inhibitors to factor V, 53-55
 - case history, 54-55
 - diagnosis, 53
 - treatment, 53-54, 55
- Acquired inhibitors to factor VIII, 51-53
 - case history, 52-53
 - diagnosis, 51-52
 - treatment, 52
- Acquired thrombotic disorders, 117-132
 - antiphospholipid syndrome, 117-121
 - hemolytic-uremic syndrome (HUSE), 128
 - heparin-induced thrombocytopenia (HIT), 128-130
 - malignancy, 122-124
 - nephrotic syndrome, 124-125
 - thrombotic thrombocytopenic purpura (TTP), 125-129
 - warfarin-induced tissue necrosis, 130-131
- Activated clotting time, 138
- Activated partial thromboplastin time (aPTT), 17-18, 17
 - prolonged, 17, 31, 39, 45, 51, 67, 74
 - reactions, 17

Activated partial thromboplastin time (aPTT)
(*continued*)
in tests for anticoagulant drugs, 137-138
in tests for coagulation factors, 31
Activated protein C (APC), 33, 34, 104
Activated protein C resistance (APCR) test, 34, 104
ADAMTS 13 enzyme, 79, 126, 127
Adenosine diphosphate (ADP), 9
Alpha 1-antitrypsin, 96
Alpha 2-antiplasmin, 13, 44. See also *Antiplasmin deficiency*
Alpha 2 macroglobulin, 13, 96
Alpha angle, 20
Antibiotics, 53
Antibodies to phospholipids, 117-121
Anticoagulant therapy, 133-145
anticoagulant drugs, 136-144
apixaban (Eliquis), 142-143
dabigatran (Pradaxa), 141
fondaparinux (Arixtra), 139-141
heparin, 136-138
Low Molecular Weight Heparin (LMWH), 138-139
rivaroxaban (Xarelto), 142
warfarin, 143-144
platelet inhibitory drugs, 133-136
aspirin, 133-134
clopidogrel (Plavix), 135-136
prasugrel (Effient), 136
Antihemophilic globulin. See *Factor VIII*.
Antiphospholipid syndrome, 117-121
case histories, 119-121
diagnosis, 118
treatment, 118-119
Antiplasmin deficiency, 76-77
Antithrombin (AT), 12, 13, 91
action mechanisms, 13, 91, 92
congenital deficiencies of, 14, 91-95
heparin and, 91, 92

Antithrombin (AT) (*continued*)
measurement of, 92, 93
newborns, levels in, 92
test for, 33
Antithrombin (AT) deficiency, 91-95
case histories, 93-95
complete deficiency as incompatible with life, 13, 92
diagnosis, 93
thrombotic disease risk and, 14, 91
treatment, 95
APCR test, 34, 104
Apixaban (Eliquis), 142-143
aPTT. See *Activated partial thromboplastin time*.
Arachidonic acid, 9-12, 29
Argatroban, 15, 18
Arixtra. See *Fondaparinux*.
Aspirin, 29, 133-134
action mechanism, 133
dosage, 133
monitoring, 133-134
AspirinWorks®, 134
AT/AT III. See *Antithrombin (AT)*.

Bernard-Soulier syndrome, 29, 87-88
Beta 2-glycoprotein 1, antibodies to, 117
Bethesda Assay, 32
Bleeding disorders
acquired, 37-57
congenital, 59-90
tests for coagulation factor defects/deficiencies,
30-32
tests involving the vascular phase, 29-30
Bleeding time, 19

C 1 inhibitor, 13
C4b-binding protein (C4BP), 13-14
CAMP (cyclic adenosine monophosphate), 12
inhibition of platelet aggregation, 14

Cardiolipin, 117, 118

Case histories

- antiphospholipid syndrome, 119-121
- antithrombin (AT) deficiency, 93-95
- application of basic screening tests, 22-28
- disseminated intravascular coagulation (DIC), 40-44
- dysfibrinogenemia, 109-111
- factor V inhibitors, 54-55
- factor V Leiden, 105-106
- factor VII deficiency, 69-70
- factor VIII deficiency, 62-63
- factor VIII inhibitors, 52-53
- factor IX deficiency, 63-64
- factor X deficiency, 65-67
- factor XII deficiency, 112-113
- factor XIII deficiency, 72-74
- fibrinogen deficiency, 75-76
- hemophilias A and B, 62-64
- heparin-induced thrombocytopenia (HIT), 130
- hyperhomocysteinemia, 116
- liver disease, 46-48
- malignancy, 123-124
- prekallikrein deficiency, 114
- protein C deficiency, 97-98
- protein S deficiency, 100-101
- prothrombin 20210A, 107-108
- thrombotic thrombocytopenic purpura (TTP), 127-128
- vitamin K deficiency, 49-50
- von Willebrand's disease, 84-85

Christmas factor. See *Factor IX*.

Clopidogrel (Plavix), 29, 135-136

- action mechanism, 135
- adverse effects, 136
- dosage, 135
- monitoring, 135

Clot formation time (CFT), 20

Clotting. See *Coagulation; Hemostasis; Vascular phase*.

Clotting time (CT), 15, 17, 20, 138

Coagulation, 9-14. See also *Anticoagulant therapy*.

- congenital bleeding disorders of, 59-78
- downregulation of, 12-13
- extrinsic pathway, 9
- intrinsic pathway, 9
- laboratory tests, 15-28
 - activated partial thromboplastin time (aPTT), 17-18, 17
 - application of basic tests, 22-28
 - Bethesda Assay for strength of coagulation factor inhibitor, 32
 - bleeding time, 19
 - case histories, 22-28
 - factor assays for factors VIII, IX, XI, and XII, 30-31
 - factor XIII assay, 31
 - fibrinogen measurement, 31-32
 - mixing tests, 18
 - platelet count, 18, 29
 - Platelet Function Analyzer, 19
 - prothrombin time (PT), 15-17, 16
 - reptilase time (RT), 32
 - specific factor assays, 30-31
 - thrombin time (TT), 15
 - thromboelastography/ometry, 19-21, 21
- normal (overview), 1-14
- pathway in normal hemostasis, 9, 10
- physiologic regulation of, 12-14

Coagulation factors, 9, 11t. See also *specific factors*.

- alternative names of, 11t
- assays for, 30-32, 70-71
- defect/deficiency assays, 30-32
- deficiencies in, 59-74
- half-lives and origins, 11t
- inhibitors of, 32, 51-55
- measurements of activity, 16

- Coagulation factors (*continued*)
 in normal hemostasis/coagulation, 10
 production in liver, 11t, 44
 specific assays for, 30-31
 tissue factor, 9, 10
 vitamin K-dependent, 44, 48, 65
- Complete blood count (CBC), 18
- Congenital bleeding disorders of coagulation, 59-78
 antiplasmin deficiency, 76-77
 factor II deficiency, 67-68
 factor V deficiency, 68
 factor VII deficiency, 69-70
 factor VIII deficiency, 59-64
 factor IX deficiency, 59-64
 factor X deficiency, 65-67
 factor XI deficiency, 64
 factor XIII deficiency, 71-74
 fibrinogen deficiency, 74-76
 hemophilia A and B, 59-64
 hemophilia C, 64
- Congenital bleeding disorders of the vascular phase,
 79-90
 Bernard-Soulier syndrome, 87-88
 Glanzmann's thrombasthenia, 85-86
 platelet storage pool disease, 88-89
 von Willebrand's disease, 79-85
- Congenital thrombotic risk factors, 91-116
 antithrombin (AT) deficiency, 14, 91-95
 dysfibrinogenemia, 108-111
 factor V Leiden, 103-106
 factor XII deficiency, 111-113
 hyperhomocysteinemia, 114-116
 plasminogen deficiency, 101-102
 prekallikrein deficiency (Fletcher Factor), 113-114
 protein C deficiency, 14, 95-98
 protein S deficiency, 14, 98-101
 prothrombin 20210A (gene mutation), 106-108
- Cyclic adenosine monophosphate. See *CAMP*.
- D-Dimer, 12-13, 39
 test for, 35-36
- Dabigatran (Pradaxa), 141-142
 action mechanism, 141
 adverse effect, 142
 dosage, 141
 monitoring, 18, 141
- DDAVP (desmopressin), 61, 85, 89
- Deep vein thrombosis (DVT)
 diagnosis of, 13
 Protein S deficiency and, 99
- Desmopressin (DDAVP), 61, 85, 89
- DIC. See *Disseminated intravascular coagulation*.
- Dilute Russell's viper venom time (dRVVT), 35
- Disseminated intravascular coagulation (DIC), 37-44
 case histories, 40-44
 causes of, 37, 38t
 chronic vs acute, 37
 differentiating from liver disease, 45-46
 laboratory diagnosis of, 37-40
 interpretation of tests, 39-40
 selection of tests, 37-39
 treatment and management, 40
- DNA analysis, 34, 104
- Dysfibrinogenemia, 108-111
- Effient. See *Prasugrel*.
- Eliquis. See *Apixaban*.
- Endothelial cells, 12, 14
- Factor I, 11t. See also *Fibrinogen*.
- Factor II, 10, 11t. See also *Prothrombin*.
- Factor II deficiency, 67-68
- Factor V, 68
 assay for, 30
 deficiency, 17, 68
 half-life and origin, 11t
 inhibitors of, 13, 53-55

- Factor V Leiden, 34, 103-106
 case history, 105-106
 diagnosis, 104
 laboratory test for, 34
 in normal hemostasis/coagulation, *10*
 prevalence of, 103-104
 treatment, 105
- Factor VII
 acquired deficiency of, 17
 activation of, 9, *10*, 15, *16*
 assay for, 30
 deficiency, 69-70
 half-life and origin, 11t
 in normal hemostasis/coagulation, *10*
- Factor VIII
 acquired inhibitors to, 51-53
 assay for, 30-31, 81
 deficiency (hemophilia A), 51, 59-64
 half-life and origin, 11t
 in normal hemostasis/coagulation, *10*
 VIIIa, inhibitors of, 13
- Factor IX
 assay for, 30-31
 deficiency (hemophilia B), 59-64
 half-life and origin, 11t, 61
 in normal hemostasis/coagulation, *10*
- Factor X
 acquired deficiency of, 17
 activation of, 15-16, *16*, 59, 65
 antithrombin (AT) and, 92
 assay for, 30
 deficiency, 65-67
 half-life and origin, 11t
 inhibition of, 13
 in normal hemostasis/coagulation, *10*
 vitamin K and, 65
- Factor XI
 assay for, 30-31
 deficiency (hemophilia C, Rosenthal syndrome), 64
 half-life and origin, 11t
 in normal hemostasis/coagulation, *10*
- Factor XII, 111
 activation of, 9, *10*, 111
 assay for, 30-31
 deficiency, 111-113
 half-life and origin, 11t
 in normal hemostasis/coagulation, *10*
- Factor XIII (fibrin stabilizing factor)
 assay for, 31
 deficiency, 71-74
 half-life and origin, 11t
 in normal hemostasis/coagulation, *10*
- Fibrin
 digestion/inhibition of, 12-13
 fibrin/fibrinogen degradation product assay, 36
 fibrin monomer test, 36
 in normal hemostasis/coagulation, *10*
- Fibrin stabilizing factor. See *Factor XIII*.
- Fibrinogen (Factor I), 74, 108
 abnormal forms of, 16, 108
 conversion to fibrin, measurement of, 15
 deficiency of, 15, 17, 74-76
 acquired deficiency, 17
 congenital deficiency, 74-76
 dysfibrinogenemia, 108-111
 fibrin/fibrinogen degradation product assay, 36
 half-life and origin, 11t
 measurement of, 31-32
 in normal hemostasis/coagulation, *10*
 prothrombin time and, 16
 reduced levels of, 16
- Fibrinogen degradation products (FDPs), 13
 testing for, 36

Fibrinolytic system, 12, 13
inhibitors of, 13
Fitzgerald factor. *See High molecular weight kininogen.*
Fletcher factor. *See Prekallikrein.*
Fondaparinux (Arixtra), 139-141
action mechanism, 139
adverse effect, 140-141
dosage, 140
monitoring, 140

Gentamicin, 53
Glanzmann's thrombasthenia, 85-86
laboratory tests for, 86
PFA-100, 86
platelet aggregation, 29, 86

Hageman factor. *See Factor XII.*
Hemolytic-uremic syndrome (HUS), 128
atypical, 128
Hemophilia A and B, 59-64
bleeding problems in, 60
case histories, 62-64
diagnosis, 60
factor VIII deficiency (hemophilia A), 51, 59
factor IX deficiency (hemophilia B), 59
in females, 59
gender and, 59
prevalence of, 59
treatment
hemophilia A, 61
hemophilia B, 61-62
Hemophilia C (Rosenthal syndrome), 64
Hemostasis. *See also Coagulation; Vascular phase.*
normal (overview), 1-14
specific laboratory tests of, 29-36

Heparin, 136-138
action mechanism, 137
adverse effects, 138
antithrombin (AT) and, 13, 91, 92
dosage, 137
Low Molecular Weight Heparin (LMWH), 138-139
monitoring, 137-138
activated clotting time, 138
aPTT, 137-138
specific heparin assay, 138
unfractionated (UFH), 15, 18
Heparin cofactor II, 102-103
Heparin-induced thrombocytopenia (HIT), 128-130,
138, 139
case history, 130
diagnosis, 129
treatment, 129-130
High molecular weight kininogen (HMWK), 110
half-life and origin, 11t
Hyperhomocysteinemia, 114-116

Idiopathic thrombocytopenic purpura (ITP), 55-56
International Normalized Ratio (INR), 16

Jewish population, hemophilia C and, 64

Kinetic time (clot formation time), 20
Kininogen (high molecular weight kininogen),
11t, 110

LA (lupus anticoagulant), 117-118
testing for, 17
Labile factor. *See Factor V.*
Laboratory tests
of coagulation, 15-28
activated partial thromboplastin time (aPTT),
17-18, 17
application of basic screening tests, 22-28

Laboratory tests (*continued*)

- bleeding time, 19
- complete blood count (CBC), 18
- mixing tests, 18
- platelet count, 18, 29
- Platelet Function Analyzer, 19
- prothrombin time (PT), 15-17, 16
- screening tests of vascular phase, 18-21
- thrombin time (TT), 15
- thromboelastography/ometry, 19-21, 21
- for Glanzmann's thrombasthenia, 86
 - PFA-100, 86
 - platelet aggregation, 29, 86
- of hemostasis, 29-36
 - antithrombin (AT), 33
 - Bethesda Assay, 32
 - coagulation factor assays, 30-32, 70-71
 - D-dimer test, 35-36
 - dilute Russell's viper venom time (dRVVT), 35
 - factor V Leiden, 34
 - fibrin/fibrinogen degradation product assay, 36
 - fibrin monomer test, 36
 - fibrinogen measurement, 31-32
 - platelet aggregation, 29-30
 - platelet count, 29
 - Protein C, 33
 - Protein S, 33-34
 - prothrombin mutation 20210A, 35
 - reptilase time (RT), 32
 - specific factor assays, 30-31
 - tests for thrombotic risk factors, 33-36
 - vascular phase, 29-30
 - von Willebrand Factor Assay, 30
- in liver disease, 45
- for von Willebrand's disease, 80-81
 - factor VIII assay, 81
 - multimer analysis, 81

Laboratory tests, for von Willebrand's disease (*continued*)

- PFA-100, 80
- platelet aggregation with ristocetin, 30, 81
- vWF-Ag assay, 80
- vWF assay (ristocetin cofactor), 30, 80
- Lepirudin, 15, 18
- Liver
 - coagulation factors produced in, 11t
 - functions of, 44
- Liver disease, 44-48
 - case histories, 46-48
 - differentiating from DIC, 45-46
 - laboratory results, typical, 45
 - treatment and management, 48
- Low Molecular Weight Heparin (LMWH), 138-139
 - antithrombin (AT) and, 13
 - heparin-induced thrombocytopenia (HIT) and, 129
- Lupus anticoagulant (LA), 17, 117-118
- Lysis index, 20

Malignancy, 122-124

- case histories, 123-124
- diagnosis, 122
- mechanisms leading to thrombosis, 122
- treatment, 123
- Maximum amplitude/maximum clot firmness (MCF), 20
- Maximum lysis (ML), 20
- Mixing tests, 18
- Multimer analysis, 81

Nephrotic syndrome, 124-125

- Normal hemostasis, overview, 1-14, 10

P2Y1 and P2Y12 receptor proteins, 9, 136
 Penicillin, 53
 PFA-100 (Platelet Function Analyzer), 19, 80, 86, 133, 134
 Phosphatidic acid, 117
 Phosphatidylethanolamine, 117
 Phosphatidylserine, 117
 Phospholipids, antibodies to, 119-121
 PK. *See Prekallikrein.*
 Plasma thromboplastin antecedent. *See Factor XI.*
 Plasmin, 12-13
 inhibitors of, 13
 Plasminogen, 101
 activation of, 12, 101
 deficiency, 101-102, 102
 acquired, 102
 congenital, 101-102
 plasminogen activator inhibitor, 13
 tissue plasminogen activator (TPA), 12, 44, 101
 Platelets
 adhesion to collagen, 9
 treatment of qualitative platelet disorders, 89
 Platelet aggregation, 9-12, 29-30, 135
 in Glanzmann's thrombasthenia, 29, 86
 inhibition of, 14
 light transmission aggregometry, 133, 134
 in nephrotic syndrome, 124, 125
 with ristocetin, 29, 30, 80, 81
 Platelet count, 18, 29, 39
 in idiopathic thrombocytopenic purpura (ITP), 55
 Platelet Function Analyzer (PFA-100), 19, 80, 86, 133, 134
 Platelet inhibitory drugs, 133-136
 aspirin, 133-134
 clopidogrel (Plavix), 135-136
 prasugrel (Effient), 136
 Platelet storage pool disease, 88-89
 Plavix. *See Clopidogrel.*
 Pradaxa. *See Dabigatran.*
 Prasugrel (Effient), 29, 136
 Prekallikrein (PK), 101, 113
 deficiency (Fletcher Factor), 113-114
 half-life and origin, 11t
 Prostacyclin, 12, 14
 Prostaglandin D2, 14
 Protein C, 12, 13, 95-96
 action mechanism, 96
 activated, 33, 34
 half-life of, 95, 131
 inhibitor, 95
 laboratory test for, 33
 vitamin K-dependence, 13, 95
 Protein C deficiency, 14, 48, 95-98
 case history, 97-98
 congenital, 95-98
 diagnosis, 6-7
 treatment, 97
 warfarin-induced tissue necrosis and, 96, 144
 Protein S, 12, 13-14, 98
 forms of, 98
 laboratory test for, 33-34
 vitamin K-dependence, 96
 Protein S deficiency, 14, 48, 98-101
 case history, 100-101
 conditions associated with, 99
 diagnosis, 99-100
 forms of, 98
 treatment, 100
 warfarin and, 99, 144
 Prothrombin (Factor II)
 assay for, 30
 conversion to thrombin, 65
 deficiency, 67-68
 half-life and origin, 11t
 in normal hemostasis/coagulation, 10
 Prothrombin complex concentrate, 61

Prothrombin 20210A (gene mutation), 35, 106-108
 case history, 107-108
 diagnosis, 106-107
 laboratory test for, 35
Prothrombin time (PT), 15-17, 16, 30
 International Normalized Ratio (INR), 16
 normal reference range, 17
 prolonged, 16-17, 39, 45, 67, 74
Pulmonary embolus (PE)
 diagnosis of, 13
 Protein S deficiency and, 99

Reptilase time (RT), 32
Risk factors for thrombotic disease, 91-116
 acquired thrombotic disorders, 117-132
 antiphospholipid syndrome, 117-121
 hemolytic-uremic syndrome (HUS), 128
 heparin-induced thrombocytopenia (HIT), 128-130
 malignancy, 122-124
 nephrotic syndrome, 124-125
 thrombotic thrombocytopenic purpura (TTP),
 125-129
 warfarin-induced tissue necrosis, 130-131
 congenital risk factors, 91-116
 antithrombin (AT) deficiency, 14, 91-95
 dysfibrinogenemia, 108-111
 factor V Leiden, 103-106
 factor XII deficiency, 111-113
 heparin cofactor II, 102-103
 hyperhomocysteinemia, 114-116
 plasminogen deficiency, 101-102
 prekallikrein deficiency, 113-114
 protein C deficiency, 14, 48, 95-98
 protein S deficiency, 14, 48, 98-101
 prothrombin 20210A (gene mutation), 35, 106-108
 liver-associated, 44-45
 tests for thrombotic risk factors, 33-36

Ristocetin, 80
 platelet aggregation with, 29, 30, 80, 81
 ristocetin cofactor, 80
Rivaroxaban (Xarelto), 142
Rosenthal syndrome (hemophilia C), 64
RT (reptilase time), 32
Russell's viper venom, 35

Serotonin, 9
Stable factor. *See Factor VII.*
Staphylokinase, 12
Streptokinase, 12
Streptomycin, 53
Stuart-Prower Factor. *See Factor X.*
Systemic lupus erythematosus (SLE), 56

Thrombin
 acquired inhibitor to, 55
 direct inhibitors, 15
 inhibition by antithrombin (AT), 13, 91-92
Thrombin time (TT), 15
 equation for, 15
 prolonged, 15, 45, 74, 77
Thrombocytopenia, 18, 44, 45
Thromboelastography/ometry, 19-21, 21
Thromboplastin. *See Activated partial thromboplastin
 time (aPTT).*
Thrombotic risk factors, 91-116. *See also Risk factors
 for thrombotic disease.*
 acquired thrombotic disorders, 117-132
 congenital risk factors, 91-116
 liver-associated, 44-45
 tests for, 33-36
Thrombotic thrombocytopenic purpura (TTP),
 125-129
 case history, 127-128
 cause of, 126
 characteristics, 125

Thrombotic thrombocytopenic purpura (TTP)
(*continued*)
diagnosis, 126-127
treatment, 127

Thromboxane, 12

Tissue factor, 9, 10, 15

Tissue plasminogen activator. See *TPA*.

TPA (tissue plasminogen activator), 12, 44, 101

Unfractionated heparin (UFH), 15
monitoring, 18

Urokinase, 12

Vascular phase, 9-12
basic screening tests of, 18-21
bleeding time, 19
platelet count, 18
Platelet Function Analyzer, 19
congenital bleeding disorders of, 79-90
Bernard-Soulier syndrome, 87-88
Glanzmann's thrombasthenia, 85-86
platelet storage pool disease, 88-89
von Willebrand's disease, 79-85
downregulation (control) of, 12, 14
physiologic regulation of, 14
specific laboratory tests of, 29-30
antithrombin (AT) test, 33
Bethesda Assay for strength of a coagulation factor inhibitor, 32
D-dimer test, 35-36
defects/deficiencies of coagulation factors, 30-32
dilute Russell's viper venom time (dRVVT), 35
factor assays for factors VIII, IX, XI, and XII, 30-31
factor V Leiden, 34
factor XIII assay, 31
fibrin/fibrinogen degradation product assay, 36
fibrin monomer test, 36

Vascular phase, specific laboratory tests (*continued*)
fibrinogen measurement, 31-32
platelet aggregation, 29-30
platelet count, 29
Protein C, 33
Protein S, 33-34
prothrombin mutation 20210A, 35
reptilase time (RT), 32
specific factor assays (factors II, V, VII, and X), 30-31
thrombotic risk factors, 33-36
von Willebrand Factor Assay, 30

Vasoconstriction, 9

Vasodilation, 14

VerifyNow® Aspirin, 134

VerifyNow® P2Y12 test, 135

Vitamin K, 48
deficiency, 48-51
associated conditions, 49
case histories, 49-50
treatment and management, 50-51
given for warfarin adverse effects, 144
proteins C and S and, 13, 95, 96
sources of, 48-49
vitamin K-dependent coagulation factors, 44, 48, 65

von Willebrand factor (vWF), 19
actions of, 79
half-life and origin, 11t
large multimers, thrombotic thrombocytopenic purpura and, 126
in normal hemostasis, 9
von Willebrand's disease, 79-85
bleeding tendency in, 80
case history, 84-85
diagnosis, 80-84
forms of, 81-83
history, typical, 79
laboratory features, 82-85

von Willebrand's disease (*continued*)

laboratory tests for, 80-81

factor VIII assay, 81

multimer analysis, 81

PFA-100, 80

platelet aggregation with ristocetin, 29, 30, 80, 81

vWF-Ag assay, 80

vWF assay (ristocetin cofactor), 30, 80

prevalence of, 79

treatment, 85

von Willebrand Factor Assay, 30, 80

Warfarin, 143-144

action mechanism, 143

adverse effects, 144

dosage, 130-131, 144

monitoring, 16, 144

vitamin K and, 49, 50

Warfarin-induced tissue necrosis, 96, 130-131, 144

Willebrand's syndrome, 29. See also *von Willebrand's disease*.

Xarelto. See *Rivaroxaban*.